Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

New agents – is the tide turning?

April 24th 2013

The last 5 years have seen a huge increase in the number of new anti-diabetes agents reaching the market, from new insulins to novel injectable and oral agents However, given changes to drug regulation following the Rosiglitazone debacle and the current financial climate, there are signs that the conveyor belt of agents is either slowing or coming to a halt. The two latest ‘blockbusters’, Novos new insulin Degludec (Tresiba) and Astra Zeneca’s SGLT2 inhibitor Dapaglafozin (Forxiga) have had major issues achieving either approval or formulary status.

Dapaglafozin ran into problems in February when NICE issued draft guidance saying that it was minded not to recommend it due to concerns about the quality and length of the trials especially where only one compared it to another active agent. There were also concerns about its cost effectiveness. This guidance has been used by local drug and therapeutics committees (DTC) to defer its formulary inclusion.

The case with Tresiba is even starker. This insulin has been gaining increasing prominence in the diabetes world – initially suggested as a once weekly agent but now marketed as a highly predictable daily basal analogue insulin. There also seems to have been some holes in Novos marketing of the insulin where its exact positioning in the therapeutic pathway is far from clear – especially as its competitor, Lantus is hardly a poor product. For example, the reduction in hypoglycaemia trumpeted at launch seems to apply to Type 2 rather than Type 1 diabetes. This aside, problems mounted in February when the FDA did not approve Tresiba pending further cardiovascular safety evidence. Furthermore, despite having received approval from European regulators, Tresiba is marketed at ~70% cost premium to Lantus (£41.50 v £72.00 for their U100 disposable pens). Given that current practice is to move away from analogue to human insulins in the majority of Type 2 diabetes due to cost effectiveness, the pricing of Tresiba does raise questions and is certainly the driver behind local DTCs not granting formulary status.

So, what is the clinician meant to make of this? Perhaps a step back is worth considering as well as more appropriate use of proven more cost effective medications such as optimal use of Metformin, human insulins unless hypoglycaemia is an issue or the really controversial step of increasing the advocacy of lifestyle changes!

Dr. Mark Freeman

Categories: Updates

Diabetes Updates Archive

calendar-iconDiabetes Updates Archive ››

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Novo NordiskNapp DiabetesSanofi DiabetesAstraZeneca

Silver Sponsors

About Ascensia Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes CareAmgen

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership